Skip to main content
رجوع
STOK logo

Stoke Therapeutics, Inc.

جودة البيانات: 100%
STOK
NASDAQ Healthcare Biotechnology
KWD 32.18
▼ KWD 1.22 (-3.65%)
القيمة السوقية: 1.90B
نطاق اليوم
KWD 31.85 KWD 33.93
نطاق 52 أسبوعًا
KWD 5.35 KWD 40.22
حجم التداول
409,419
متوسط 50 يوم / 200 يوم
KWD 32.73 / KWD 24.99
الإغلاق السابق
KWD 33.40

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -276.5 0.3
P/B 5.4 2.9
ROE % -2.4 3.7
Net Margin % -3.7 3.8
Rev Growth 5Y % 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 42.750 +32.8%
Low: KWD 35.000 High: KWD 60.000
ربحية السهم المستقبلية
-KWD 3.378
الإيرادات المقدّرة
27 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2029 KWD 0.083
KWD 0.004 – KWD 0.183
340 M 6
FY2028 -KWD 2.149
-KWD 3.434 – -KWD 0.687
120 M 8
FY2027 -KWD 3.161
-KWD 3.771 – -KWD 2.050
49 M 9

النقاط الرئيسية

Debt/Equity of 0.00 — conservative balance sheet
Generating 44.92M in free cash flow
Capital efficient — spends only 0.36% of revenue on capex

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)404.50%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-2.37%
ROIC-4.38%
Net Margin-3.73%
Op. Margin-11.16%

الأمان

Debt / Equity
0.00
Current Ratio5.28
Interest Coverage-1.50

التقييم

P/E Ratio
-276.47
P/B Ratio5.40
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 404.50% Revenue Growth (3Y) 358.31%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 184.42M Net Income (TTM) -6.89M
ROE -2.37% ROA -1.65%
Gross Margin 100.00% Operating Margin -11.16%
Net Margin -3.73% Free Cash Flow (TTM) 44.92M
ROIC -4.38% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 5.28
Interest Coverage -1.50 Dividend Yield 0.00%
Valuation
P/E Ratio -276.47 P/B Ratio 5.40
P/S Ratio 10.32 PEG Ratio 2.94
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.90B Enterprise Value 1.82B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 184.42M 36.56M 8.78M 12.41M 0.0
Net Income -6.89M -88.98M -104.70M -101.07M -85.81M
EPS (Diluted) -0.12 -1.65 -2.38 -2.60 -2.34
Gross Profit 184.42M 36.56M 8.78M 12.41M 0.0
Operating Income -20.59M -101.37M -114.77M -104.36M -86.07M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 418.43M 271.56M 228.34M 256.07M 238.87M
Total Liabilities 65.98M 42.53M 68.78M 71.22M 21.09M
Shareholders' Equity 352.46M 229.02M 159.57M 184.85M 217.78M
Total Debt 0.0 2.32M 2.06M 2.36M 1.51M
Cash & Equivalents 84.22M 127.98M 191.44M 113.56M 144.90M
Current Assets 305.70M 232.76M 215.34M 244.07M 229.22M
Current Liabilities 57.88M 40.06M 30.82M 31.39M 17.14M